AptarGroup to Announce Q4 Earnings Amid Cautious Market Outlook
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 23 2026
0mins
Should l Buy ATR?
Source: seekingalpha
AptarGroup (ATR) shares fell 5.01% as the stock crossed below the 5-day SMA, reflecting broader market weakness with the Nasdaq-100 down 1.22% and the S&P 500 down 1.07%.
The company is set to release its Q4 earnings on February 5th, with a consensus EPS estimate of $1.23, indicating a 17.4% year-over-year decline. Revenue is projected at $878.58 million, suggesting a 3.6% year-over-year growth. However, the lack of upward revisions for EPS estimates and multiple downward adjustments for revenue estimates reflect a cautious market outlook, which may impact investor confidence.
As AptarGroup prepares for its earnings announcement, the mixed expectations could lead to volatility in its stock price. The company's historical performance shows it has beaten EPS estimates 75% of the time, but challenges in revenue growth remain a concern.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ATR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ATR
Wall Street analysts forecast ATR stock price to rise
4 Analyst Rating
1 Buy
3 Hold
0 Sell
Hold
Current: 124.730
Low
133.00
Averages
145.33
High
156.00
Current: 124.730
Low
133.00
Averages
145.33
High
156.00
About ATR
AptarGroup, Inc. is engaged in the design and manufacturing of drug and consumer product dosing, dispensing, and protection technologies. The Company serves diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care, and home care. It also manufactures and sells elastomeric primary packaging components. It operates through three segments, which include Pharma segment, Beauty segment, and Closures segment. The Pharma segment is a supplier of nasal drug delivery spray pumps and metered dose inhaler valves (MDIs) to the pharmaceutical and health care markets worldwide. The Beauty segment sells pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care, and home care markets. The Closures segment includes dispensing and non-dispensing solutions that enable product delivery without removal of the cap and are used across multiple consumer end markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Aptar Named One of America's Climate Leaders for Fourth Consecutive Year
- Recognition as Climate Leader: AptarGroup has been named one of America's Climate Leaders by USA Today for the fourth consecutive year, reflecting the company's long-term commitment to sustainability and climate action, thereby enhancing its market reputation in environmental stewardship.
- Emission Reduction Achievements: Since its 2019 baseline year, Aptar has achieved significant reductions in Scope 1 and Scope 2 emissions, indicating effective measures in reducing climate impact and further solidifying its leadership position in the industry.
- Science-Based Targets: Aptar's science-based targets align with the goal of limiting global warming to 1.5°C, aiming for reductions in renewable electricity use and Scope 3 emissions by 2030, showcasing its proactive strategies in addressing climate change.
- Global Recognition and Engagement: Aptar has been recognized by CDP with an
See More
Aptar Partners with Enable for enFuse® Digital Health Solution
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement throughout the injection process.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater confidence and control over the treatment process, thereby improving adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, supporting pharmaceutical partners across the entire drug development lifecycle from clinical trials to commercialization, enhancing the therapeutic value.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions in clinical development and market readiness, ultimately improving the patient treatment journey.
See More
Aptar Digital Health Partners with Enable Injections for enFuse® System
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement during the injection process, thereby boosting treatment confidence.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater control and confidence over the treatment process, which is expected to improve adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, enabling pharmaceutical partners to enhance the value of their therapies throughout the drug development lifecycle, from clinical trials to commercialization, aligning with market needs.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions during clinical development and launch readiness, ultimately driving improved patient treatment outcomes.
See More
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
Aptar Pharma Supports Development of Next-Gen Nasal Spray
- Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
- Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
- Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
- Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
Aptar Named One of America's Climate Leaders for Fourth Consecutive Year
- Recognition as Climate Leader: AptarGroup has been named one of America's Climate Leaders by USA Today for the fourth consecutive year, reflecting the company's long-term commitment to sustainability and climate action, thereby enhancing its market reputation in environmental stewardship.
- Emission Reduction Achievements: Since its 2019 baseline year, Aptar has achieved significant reductions in Scope 1 and Scope 2 emissions, indicating effective measures in reducing climate impact and further solidifying its leadership position in the industry.
- Science-Based Targets: Aptar's science-based targets align with the goal of limiting global warming to 1.5°C, aiming for reductions in renewable electricity use and Scope 3 emissions by 2030, showcasing its proactive strategies in addressing climate change.
- Global Recognition and Engagement: Aptar has been recognized by CDP with an
See More
Aptar Partners with Enable for enFuse® Digital Health Solution
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement throughout the injection process.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater confidence and control over the treatment process, thereby improving adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, supporting pharmaceutical partners across the entire drug development lifecycle from clinical trials to commercialization, enhancing the therapeutic value.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions in clinical development and market readiness, ultimately improving the patient treatment journey.
See More
Aptar Digital Health Partners with Enable Injections for enFuse® System
- Strategic Partnership: Aptar Digital Health has formed a strategic partnership with Enable Injections, becoming the preferred digital health partner for the enFuse® system, aimed at enhancing patient experience and engagement during the injection process, thereby boosting treatment confidence.
- Digital Solution Features: The new solution will include features such as treatment data recording, onboarding modules, injection guidance, and symptom tracking, empowering patients and caregivers with greater control and confidence over the treatment process, which is expected to improve adherence.
- Flexible Architecture Design: Built on a flexible and scalable architecture, the solution will be deployed alongside the enFuse® system, enabling pharmaceutical partners to enhance the value of their therapies throughout the drug development lifecycle, from clinical trials to commercialization, aligning with market needs.
- Data-Driven Decision Making: By capturing adherence data and patient-reported outcomes remotely and providing actionable insights through analytics dashboards, the solution will assist pharmaceutical companies in making more informed decisions during clinical development and launch readiness, ultimately driving improved patient treatment outcomes.
See More
Key Wall Street Rating Updates on Friday
- Nvidia Rating Reaffirmed: Wolfe maintains Nvidia as an outperform, stating that with the stock priced at just 13x their bull case EPS, it is too cheap to ignore, potentially attracting more investor interest.
- Arm Upgrade: HSBC upgrades Arm from reduce to buy, highlighting its strong positioning in the AI sector, suggesting that its transition to a major AI server CPU player presents a significant undervaluation opportunity for investors.
- Apple App Store Revenue Slowdown: Morgan Stanley reiterates Apple as overweight, noting that App Store revenue growth decelerated to 6% YoY in Q1 2023, falling short of the expected 8%, indicating market caution regarding Apple's future growth prospects.
- Oneok Upgrade: Jefferies upgrades Oneok from hold to buy, citing tangible upside potential in the current market environment, particularly as geopolitical tensions in the Middle East raise crude oil price risks.
See More
Aptar Pharma Supports Development of Next-Gen Nasal Spray
- Clinical Study Progress: Aptar Pharma's UDS Powder Nasal Spray System is being utilized in ENA Respiratory's Phase II clinical study of INNA-051, aimed at evaluating its potential to protect against symptomatic viral respiratory infections, marking a significant innovation effort in respiratory health.
- Technical Advantages: The UDS system is designed to deliver a single, precise dose of dry powder, ensuring consistent performance in clinical development settings, thereby enhancing drug reliability and patient experience, which is crucial for market competitiveness.
- Moisture Protection: The nasal delivery system features Aptar CSP Technologies' innovative container closure system, incorporating 3-Phase Activ-Polymer™ technology to effectively protect the powder formulation from moisture, ensuring stability and efficacy to meet market demands for high-quality drug delivery.
- Strategic Collaboration: The partnership between Aptar Pharma and ENA Respiratory not only showcases its leadership in drug delivery technologies but also reflects the company's strategic direction towards developing non-vaccine approaches to address respiratory diseases, further solidifying its influence in the pharmaceutical industry.
See More
AptarGroup Appoints Gael Touya as New CEO Effective September 2026
- Leadership Transition: AptarGroup has announced that Gael Touya will succeed Stephan B. Tanda as CEO effective September 1, 2026, with Tanda remaining as an advisor to ensure a smooth transition, highlighting the company's focus on future growth.
- Strategic Growth: With over 30 years at Aptar, Gael has driven 82% revenue growth as President of Aptar Pharma, showcasing his leadership in drug delivery, and will continue to expand strategies in consumer markets.
- Operational Efficiency: Under Gael's leadership, Aptar Pharma has integrated technologies and services to enhance customer efficiency from early development to commercialization, strengthening the company's competitive position in the global drug delivery market.
- Sustainability Commitment: During Stephan's tenure, Aptar's adjusted EBITDA margins increased from 19% in 2017 to 22% in 2025, alongside significant advancements in sustainability, reflecting the company's commitment to environmental responsibility.
See More
